Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

Just as we got used to the idea that antipsychotic medications needed to block both dopamine and serotonin receptors, specifically the D-2 receptor and the 5HT-2A receptor, and these (somewhat ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...

About half of the estimated 15.5 million American adults who have ADHD were diagnosed during adulthood. UAB’s Rachel Fargason ...

5-HT 3, serotonin-receptor-3; 5-HT 4, serotonin-receptor-4; D2, dopamine-receptor 2; IM, intramuscular; IV, intravenous; SC, subcutaneous. Chris Rayner is the Gwendolyn Michell Senior Lecturer in ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

This may be the last edition that comes before the Surge pulls a Bezos and pre-obeys the incoming administration by ...

By the criteria of the World Health Organisation 1-2% of British children and adolescents qualify ... Their effectiveness, ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.